Today, medical science is on the cutting edge of innovation with new treatments, called gene therapies, entering the market faster than ever before. Gene therapies modify genes or replace faulty genes with healthy ones to treat, cure or prevent disease.

Because these therapies are complex and costly to develop, they can carry large upfront price tags. These high prices combined with the current US reimbursement system, which is largely based on volume of sales and standards of care rather than outcomes achieved, means that accessing gene therapies can be extremely challenging for patients.

Join CAHC’s Campaign for Transformative Therapies for a virtual briefing to learn more about:

What gene therapies are;

• The disease states being targeted by current and near-future therapies;
• Lessons learned about reimbursement hurdles in our current health care market; and
• Federal barriers that need to be fixed to ensure future patient access.

View Recorded Seminar Here

Speakers Include:

• Brett Kopelan, Executive Director, debra of America
• Glenn Pierce, MD, PhD, VP, Medical, World Federation of Hemophilia
  • Glenn’s Slides
• Sarah Pitluck, VP & Head of Global Pricing & Reimbursement, Spark Therapeutics
• Paul Howard, PhD, Director of Public Policy, Amicus Therapeutics
  • Paul’s Slides
• Sloane Salzburg, Vice President, Council for Affordable Health Coverage, Moderator